The Act was formally presented to the President on April 2, 2026
Ipamorelin is a selective growth hormone releasing peptide (GHRP), a synthetic pentapeptide that binds to the ghrelin receptor (GHS-R1a) in the pituitary gland, triggering the release of growth hormone (GH)
This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States. Noom reports strong early outcomes with microdosing strategy This gradual approach referenced by Egler is Nooms low and slow titration approach with microdoses, which are considered fractions of the standard medication doses, 25% or less
SGLT2i alone
GLP-1s for Weight Loss Online Treatment
In SURMOUNT-1, 91% lost at least 5%, 79% lost at least 15%, and 36% lost at least 25%